window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : September 24, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Therapeutic Areas

  • Clinical & Regulatory,Research & Development,Therapeutic Areas

    Hearing aids linked to lower dementia risk in adults with epilepsy

    Adults with epilepsy and hearing loss who use hearing aids [...]

    June 30, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Cereno reports positive 12-month CS1 safety data ahead of Phase 2b PAH trial

    Cereno Scientific has reported encouraging 12-month safety and clinical observations [...]

    June 29, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    China IgA nephropathy approval highlights rising dual-target biologic competition

    China’s approval of a first dual BAFF/APRIL therapy in IgA [...]

    June 25, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Racura treats first patient in Harness-1 lung cancer trial

    Racura Oncology has treated the first patient in its Harness-1 [...]

    June 25, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Research & Development,Therapeutic Areas

    EMBARC announces intention to collaborate with Insmed on landmark interventional study in bronchiectasis

    EMBARC has announced its intention to collaborate with Insmed on [...]

    June 28, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    Orphan Therapeutics Accelerator expands rare disease development network to advance ultra-rare therapies

    Orphan Therapeutics Accelerator has expanded its development network for ultra-rare [...]

    June 24, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Phase 2 trial begins for fetal growth restriction therapy with no approved drug treatments available

    The first patients have been dosed in a Phase 2 [...]

    June 24, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Oral GLP-1 candidate CX11 achieves 11.5% weight loss in US Phase 2 obesity trial

    CORXEL Pharmaceuticals reported positive Phase 2 results for oral GLP-1 [...]

    June 24, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    NICE recommends cemiplimab for recurrent or metastatic cervical cancer

    NICE has recommended cemiplimab for eligible adults with recurrent or [...]

    June 24, 2026
  • Advanced Therapies,Biotech & Pharma Business,Drug Discovery & Development,Genomics and sequencing,Therapeutic Areas

    Meteor Biotech joins South Korea consortium to advance brain organoid commercialisation platform

    Meteor Biotech has joined a South Korean government-backed consortium aimed [...]

    June 23, 2026
Previous101112Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • FDA approves daraxonrasib for second-line pancreatic cancer
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics
  • PharmaForceIQ launches AI platform for pharma commercial teams
    Categories: Biotech & Pharma Business, Digital & Data
  • Biogen’s felzartamab approved in China for multiple myeloma
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Pharmaceuticals and therapeutics
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top